Clinical Trials Directory

Trials / Completed

CompletedNCT02877654

Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins in IBS Patients?

Assessment of Intestinal Barrier in Irritable Bowel Syndrome Patients : Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins ?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
67 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Increased intestinal permeability is one of the main pathophysiological mechanisms involved in irritable bowel syndrome. The expression of some intestinal tight junction proteins is decreased mostly in IBS-diarrhoea patients. This decrease is correlated with increased intestinal permeability. Currently, no test used in clinical practice could assess intestinal permeability. We hypothesis plasmatic zonulin could reflect intestinal permeability in IBS patients.

Detailed description

The goal of our study is to look for a correlation between plasmatic zonulin and increased colonic permeability (assessed by the expression of intestinal tight junction proteins by western blot) in IBS patients and to look for a role of intestinal low-grade inflammation and microbiota. Population : IBS patients with diarrhoea or IBS with constipation or mixed with worsening of symptoms Outcomes measures : Plasmatic zonulin (ELISA kit) Occludin expression in colonic biopsies (western blot)

Conditions

Interventions

TypeNameDescription
PROCEDUREcolonoscopy with biopsies in the left colon to assess intestinal permeabilityEleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1. One blood sample is taken to assess plasmatic zonulin (ELISA kit).

Timeline

Start date
2017-02-02
Primary completion
2021-05-20
Completion
2021-05-20
First posted
2016-08-24
Last updated
2022-05-26

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02877654. Inclusion in this directory is not an endorsement.